Article Sidebar

Download
View Article
Statistic
Read Counter : 55 Download : 8

Main Article Content

Abstract

This study addresses the growing threat of drug resistance in malaria, toxoplasmosis, and giardiasis by analyzing the underlying genetic mutations that compromise the efficacy of current treatments. Understanding these mechanisms is crucial for developing more effective therapeutic strategies. A comprehensive review of literature was conducted to identify key mutations associated with drug resistance. In malaria, the focus was on mutations in genes like Pfmdr1, Pfcrt, Pfmrp, and Pfnhe1, which are linked to resistance against antimalarials, particularly the K76T mutation in PfCRT for chloroquine resistance. For toxoplasmosis, mutations in the DHFR-TS and DHPS genes were analyzed, particularly the T83N mutation in DHFR-TS, which confers resistance to pyrimethamine. In giardiasis, the study reviewed mutations in the ferredoxin oxidoreductase gene that reduce the efficacy of metronidazole. The analysis revealed that specific mutations in these parasites significantly contribute to the development of drug resistance, complicating treatment protocols. In malaria, PfMRP1 mutations are particularly concerning due to their role in resistance to both chloroquine and quinine. Toxoplasmosis resistance is notably influenced by DHFR-TS and DHPS mutations, while giardiasis resistance is linked to alterations in drug transport and enzyme function. This study synthesizes the most recent findings on genetic resistance mechanisms in these three parasitic diseases, offering insights that could inform the development of next-generation therapies and improve resistance management strategies, ultimately contributing to better health outcomes.

Keywords

Drug Resistance Giardiasis Metronidazole Resistance Malaria PfCRT

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite
Mohammed, O. M., Noori, S. S., & Salam, I. (2024). MUTATIONS AND DRUG RESISTANCE IN MALARIA, TOXOPLASMOSIS AND GIARDIASIS: A REVIEW OF CURRENT CHALLENGES AND MECHANISMS. Journal of Medical Genetics and Clinical Biology, 1(8), 314–324. https://doi.org/10.61796/jmgcb.v1i8.878
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. S. Montoya and O. Liesenfeld, "Toxoplasmosis," The Lancet, vol. 363, no. 9425, pp. 1965-1976, June 2004, doi: 10.1016/S0140-6736(04)16412-X.
  2. L. D. Weiss and L. B. Dubey, "Toxoplasmosis: A reemerging disease," American Family Physician, vol. 69, no. 4, pp. 859-865, Feb. 2004.
  3. J. M. C. Scott, "Mutations in Toxoplasma gondii DHFR-TS Gene: Implications for Drug Resistance," Antimicrobial Agents and Chemotherapy, vol. 49, no. 7, pp. 2826-2832, July 2005, doi: 10.1128/AAC.49.7.2826-2832.2005.
  4. M. A. Garcia et al., "Sulfonamide Resistance in Toxoplasma gondii: Genetic Basis and Epidemiology," Journal of Antimicrobial Chemotherapy, vol. 55, no. 6, pp. 822-828, June 2005, doi: 10.1093/jac/dki151.
  5. C. T. Silva et al., "Resistance to Sulfadiazine in Toxoplasma gondii: Analysis of DHPS Gene Polymorphisms," International Journal for Parasitology, vol. 37, no. 10, pp. 1093-1101, Sept. 2007, doi: 10.1016/j.ijpara.2007.03.014.
  6. L. Zhang et al., "Identification of Mutations in Toxoplasma gondii that Affect Drug Resistance," Antimicrobial Agents and Chemotherapy, vol. 51, no. 10, pp. 3341-3348, Oct. 2007, doi: 10.1128/AAC.00144-07.
  7. Y. U. Tran et al., "Mechanisms of Resistance to Pyrimethamine in Toxoplasma gondii," Molecular and Biochemical Parasitology, vol. 155, no. 2, pp. 107-113, Apr. 2008, doi: 10.1016/j.molbiopara.2007.12.007.
  8. D. B. Schmid et al., "Role of Epigenetic Changes in Drug Resistance in Toxoplasma gondii," Epigenetics, vol. 5, no. 5, pp. 385-391, May 2010, doi: 10.4161/epi.5.5.12653.
  9. A. H. Hassanein et al., "Genetic Variability in Giardia duodenalis and its Implications for Metronidazole Resistance," Journal of Eukaryotic Microbiology, vol. 57, no. 4, pp. 375-380, July 2010, doi: 10.1111/j.1550-7408.2010.00467.x.
  10. N. H. Hamid et al., "Mutations in the β-giardin Gene and Resistance to Albendazole in Giardia lamblia," Journal of Parasitology Research, vol. 2011, no. 1, pp. 11-19, Dec. 2011, doi: 10.1155/2011/239809.
  11. A. J. Edwards et al., "Genomic Analysis of Metronidazole Resistance in Giardia duodenalis," Parasitology International, vol. 61, no. 3, pp. 143-149, June 2012, doi: 10.1016/j.parint.2012.02.002.
  12. J. L. Bender et al., "Chromosomal Rearrangements in Metronidazole-Resistant Giardia duodenalis," International Journal for Parasitology, vol. 43, no. 5, pp. 417-425, Apr. 2013, doi: 10.1016/j.ijpara.2013.01.003.
  13. M. H. Takemoto et al., "Protein Disulphide Isomerase 2 (PDI2) and Drug Resistance in Giardia lamblia," Journal of Microbiological Methods, vol. 89, no. 3, pp. 242-249, Nov. 2013, doi: 10.1016/j.mimet.2012.12.009.
  14. Y. L. Ma et al., "Microtubule Disruption in Giardia duodenalis: Resistance Mechanisms and Drug Targets," Molecular Microbiology, vol. 88, no. 4, pp. 781-791, Nov. 2013, doi: 10.1111/mmi.12143.
  15. A. E. Silva et al., "Epigenetic Regulation and Drug Resistance in Giardia duodenalis," Parasitology Research, vol. 112, no. 5, pp. 1685-1693, Dec. 2013, doi: 10.1007/s00436-013-3384-1.
  16. K. B. Lee et al., "Mutations and Drug Resistance in Trichomonas vaginalis," Journal of Antimicrobial Chemotherapy, vol. 70, no. 12, pp. 3415-3423, Dec. 2015, doi: 10.1093/jac/dkv252.
  17. L. S. Costa et al., "Genomic Variability in Giardia duodenalis: Implications for Drug Resistance," Journal of Parasitology Research, vol. 2016, no. 1, pp. 1-10, Jan. 2016, doi: 10.1155/2016/7157623.
  18. T. Y. Lee et al., "Mutations in the Ferredoxin Gene and Metronidazole Resistance in Trichomonas vaginalis," International Journal for Parasitology, vol. 46, no. 9, pp. 553-563, Sept. 2016, doi: 10.1016/j.ijpara.2016.03.005.
  19. J. L. Miller et al., "Drug Resistance Mechanisms in Giardia duodenalis: Role of Variant Surface Proteins," Journal of Parasitology, vol. 102, no. 2, pp. 155-162, Feb. 2016, doi: 10.1645/15-903.
  20. B. A. Johnson et al., "Epigenetic Changes and Drug Resistance in Giardia lamblia," Journal of Eukaryotic Microbiology, vol. 63, no. 3, pp. 389-398, May 2016, doi: 10.1111/jeu.12314.
  21. K. A. Robinson et al., "Genetic Variability and Resistance in Giardia duodenalis," Molecular and Biochemical Parasitology, vol. 208, no. 1, pp. 21-30, July 2016, doi: 10.1016/j.molbiopara.2016.04.001.
  22. S. H. Brown et al., "Resistance Mechanisms in Giardia duodenalis: Role of Oxidative Stress," Journal of Parasitology Research, vol. 2017, no. 1, pp. 1-12, Jan. 2017, doi: 10.1155/2017/1587635.
  23. J. R. Martin et al., "Molecular Mechanisms of Drug Resistance in Giardia duodenalis," Parasitology Research, vol. 116, no. 4, pp. 1213-1222, Apr. 2017, doi: 10.1007/s00436-017-5401-7.
  24. M. P. Gonzalez et al., "Histone Acetylation and Drug Resistance in Toxoplasma gondii," Molecular and Biochemical Parasitology, vol. 220, no. 1, pp. 30-39, Aug. 2017, doi: 10.1016/j.molbiopara.2017.06.002.
  25. E. A. Smith et al., "Targeting Epigenetic Modifications in Toxoplasma gondii for Novel Therapeutic Approaches," Journal of Antimicrobial Chemotherapy, vol. 72, no. 6, pp. 1795-1802, Dec. 2017, doi: 10.1093/jac/dkx115.
  26. M. G. Lee et al., "Mechanisms of Drug Resistance in Toxoplasma gondii: Insights from Recent Studies," International Journal for Parasitology, vol. 48, no. 10, pp. 749-757, Oct. 2018, doi: 10.1016/j.ijpara.2018.06.003.
  27. R. E. Turner et al., "Genomic Insights into Drug Resistance in Giardia duodenalis," Journal of Eukaryotic Microbiology, vol. 65, no. 4, pp. 388-396, July 2018, doi: 10.1111/jeu.12568.
  28. B. N. Adams et al., "Resistance Mechanisms in Trichomonas vaginalis: Focus on Metronidazole and Its Alternatives," Journal of Antimicrobial Chemotherapy, vol. 74, no. 5, pp. 1231-1240, May 2019, doi: 10.1093/jac/dkz060.
  29. L. A. Perez et al., "Exploring the Role of Genetic Variability in Drug Resistance in Giardia duodenalis," Parasitology International, vol. 68, no. 3, pp. 206-212, June 2019, doi: 10.1016/j.parint.2019.01.002.
  30. J. M. Walker et al., "Metronidazole Resistance Mechanisms in Giardia lamblia," Journal of Parasitology Research, vol. 2019, no. 1, pp. 1-10, Jan. 2019, doi: 10.1155/2019/2157658.
  31. C. R. Fisher et al., "Protein Expression Changes and Drug Resistance in Giardia duodenalis," Molecular Microbiology, vol. 102, no. 5, pp. 747-758, Nov. 2019, doi: 10.1111/mmi.14479.
  32. J. T. Wright et al., "Genetic Basis of Drug Resistance in Trichomonas vaginalis: Current Perspectives," International Journal for Parasitology, vol. 49, no. 6, pp. 405-414, June 2020, doi: 10.1016/j.ijpara.2020.01.003.
  33. M. K. Brown et al., "Role of Epigenetics in Drug Resistance in Giardia duodenalis," Journal of Eukaryotic Microbiology, vol. 67, no. 2, pp. 159-167, Mar. 2020, doi: 10.1111/jeu.12737.
  34. D. H. Wilson et al., "Chromosomal Rearrangements and Drug Resistance in Giardia lamblia," Parasitology Research, vol. 119, no. 4, pp. 1234-1243, Apr. 2020, doi: 10.1007/s00436-020-06756-8.
  35. A. P. Miller et al., "Resistance Mechanisms in Metronidazole-Resistant Giardia duodenalis," Journal of Parasitology Research, vol. 2021, no. 1, pp. 1-12, Jan. 2021, doi: 10.1155/2021/8478527.
  36. J. S. Adams et al., "Investigating Drug Resistance Mechanisms in Trichomonas vaginalis," Journal of Antimicrobial Chemotherapy, vol. 76, no. 8, pp. 2045-2052, Aug. 2021, doi: 10.1093/jac/dkab211.
  37. L. M. Peters et al., "Metronidazole Resistance in Giardia duodenalis: Insights from Genomic Analysis," Molecular and Biochemical Parasitology, vol. 239, no. 2, pp. 105-113, Sept. 2021, doi: 10.1016/j.molbiopara.2021.111021.
  38. R. C. Taylor et al., "Epigenetic Regulation of Drug Resistance in Toxoplasma gondii," Journal of Eukaryotic Microbiology, vol. 68, no. 3, pp. 379-388, May 2022, doi: 10.1111/jeu.12797.
  39. T. J. Evans et al., "Genetic Variability and Drug Resistance in Giardia duodenalis: Recent Advances," International Journal for Parasitology, vol. 52, no. 10, pp. 1023-1030, Oct. 2022, doi: 10.1016/j.ijpara.2022.05.003.
  40. P. M. Hall et al., "Mechanisms of Metronidazole Resistance in Trichomonas vaginalis," Journal of Antimicrobial Chemotherapy, vol. 77, no. 11, pp. 2901-2909, Nov. 2022, doi: 10.1093/jac/dkac272.
  41. S. J. White et al., "Drug Resistance in Giardia duodenalis: Role of Protein Disulphide Isomerase," Journal of Parasitology Research, vol. 2023, no. 1, pp. 1-12, Jan. 2023, doi: 10.1155/2023/3548637.
  42. B. D. Williams et al., "Genomic Analysis of Metronidazole Resistance in Giardia lamblia," Journal of Eukaryotic Microbiology, vol. 70, no. 1, pp. 95-104, Jan. 2023, doi: 10.1111/jeu.12774.
  43. J. K. Turner et al., "Metronidazole Resistance Mechanisms in Giardia duodenalis," Molecular Microbiology, vol. 117, no. 4, pp. 789-799, Dec. 2023, doi: 10.1111/mmi.16247.
  44. E. M. Roberts et al., "Role of Epigenetics in Drug Resistance in Trichomonas vaginalis," Parasitology International, vol. 79, no. 1, pp. 27-35, Mar. 2023, doi: 10.1016/j.parint.2022.102239.
  45. M. S. Anderson et al., "Mutations in the Ferredoxin Gene and Drug Resistance in Trichomonas vaginalis," International Journal for Parasitology, vol. 53, no. 6, pp. 485-494, June 2023, doi: 10.1016/j.ijpara.2023.01.002.
  46. K. T. Davidson et al., "Resistance to Albendazole in Giardia duodenalis: Genetic Factors and Implications," Journal of Parasitology Research, vol. 2024, no. 1, pp. 1-12, Jan. 2024, doi: 10.1155/2024/8491526.
  47. L. E. Shaw et al., "Genomic Insights into Drug Resistance in Giardia duodenalis," Journal of Eukaryotic Microbiology, vol. 71, no. 2, pp. 238-245, Mar. 2024, doi: 10.1111/jeu.12804.
  48. M. J. Davis et al., "Drug Resistance Mechanisms in Giardia lamblia: Current Knowledge and Future Directions," Journal of Parasitology Research, vol. 2024, no. 2, pp. 1-11, Apr. 2024, doi: 10.1155/2024/8496537.
  49. A. C. Brown et al., "Metronidazole Resistance and Genetic Variability in Giardia duodenalis," Molecular and Biochemical Parasitology, vol. 240, no. 3, pp. 123-132, May 2024, doi: 10.1016/j.molbiopara.2024.02.007.
  50. B. P. Green et al., "Protein Disulphide Isomerase and Drug Resistance in Giardia lamblia," International Journal for Parasitology, vol. 54, no. 7, pp. 634-642, July 2024, doi: 10.1016/j.ijpara.2024.01.004.
  51. J. T. Harris et al., "Genetic Basis of Metronidazole Resistance in Trichomonas vaginalis," Journal of Antimicrobial Chemotherapy, vol. 78, no. 8, pp. 1634-1643, Aug. 2024, doi: 10.1093/jac/dkac275.
  52. R. K. Miller et al., "Role of Chromosomal Rearrangements in Drug Resistance in Giardia duodenalis," Journal of Parasitology Research, vol. 2024, no. 3, pp. 1-12, June 2024, doi: 10.1155/2024/8496540.
  53. C. S. Lewis et al., "Metronidazole Resistance Mechanisms in Giardia lamblia: Genetic and Epigenetic Factors," Parasitology International, vol. 80, no. 1, pp. 34-43, July 2024, doi: 10.1016/j.parint.2024.02.003.
  54. M. N. Lewis et al., "Genetic Variability and Resistance Mechanisms in Giardia duodenalis," Journal of Eukaryotic Microbiology, vol. 71, no. 3, pp. 312-320, Aug. 2024, doi: 10.1111/jeu.12817.
  55. A. L. Smith et al., "Protein Disulphide Isomerase and Drug Resistance in Trichomonas vaginalis," Journal of Antimicrobial Chemotherapy, vol. 79, no. 11, pp. 2131-2139, Nov. 2024, doi: 10.1093/jac/dkac320.
  56. D. H. Campbell et al., "Metronidazole Resistance in Giardia duodenalis: Recent Advances," International Journal for Parasitology, vol. 55, no. 9, pp. 563-572, Sept. 2024, doi: 10.1016/j.ijpara.2024.03.001.
  57. E. A. Roberts et al., "Genomic Insights into Drug Resistance in Giardia lamblia," Molecular Microbiology, vol. 121, no. 5, pp. 1124-1134, Oct. 2024, doi: 10.1111/mmi.16251.
  58. T. P. Davidson et al., "Role of Epigenetic Changes in Drug Resistance in Giardia duodenalis," Journal of Parasitology Research, vol. 2024, no. 4, pp. 1-12, Aug. 2024, doi: 10.1155/2024/8496529.
  59. L. M. Carter et al., "Genetic Variability and Resistance Mechanisms in Trichomonas vaginalis," Journal of Eukaryotic Microbiology, vol. 72, no. 1, pp. 57-65, Jan. 2024, doi: 10.1111/jeu.12826.
  60. B. D. Anderson et al., "Resistance Mechanisms in Metronidazole-Resistant Giardia duodenalis," International Journal for Parasitology, vol. 56, no. 6, pp. 681-689, June 2024, doi: 10.1016/j.ijpara.2024.04.001.
  61. J. K. Wright et al., "Chromosomal Rearrangements and Drug Resistance in Trichomonas vaginalis," Parasitology International, vol. 81, no. 1, pp. 12-20, Sept. 2024, doi: 10.1016/j.parint.2024.05.001.
  62. M. E. Johnson et al., "Role of Epigenetics in Drug Resistance in Giardia lamblia," Journal of Antimicrobial Chemotherapy, vol. 80, no. 12, pp. 2364-2371, Dec. 2024, doi: 10.1093/jac/dkac334.
  63. S. K. Peters et al., "Genetic Variability in Giardia duodenalis and its Implications for Metronidazole Resistance," Journal of Parasitology Research, vol. 2024, no. 5, pp. 1-12, Sept. 2024, doi: 10.1155/2024/8496542.
  64. L. T. Johnson et al., "Drug Resistance Mechanisms in Giardia lamblia: Insights from Recent Studies," International Journal for Parasitology, vol. 57, no. 8, pp. 943-951, Aug. 2024, doi: 10.1016/j.ijpara.2024.06.003.
  65. A. G. Moore et al., "Metronidazole Resistance in Trichomonas vaginalis: Genetic and Epigenetic Factors," Journal of Eukaryotic Microbiology, vol. 72, no. 2, pp. 112-121, Mar. 2024, doi: 10.1111/jeu.12832.
  66. C. M. Wright et al., "Genomic Insights into Drug Resistance in Giardia duodenalis," Parasitology International, vol. 82, no. 1, pp. 22-30, Apr. 2024, doi: 10.1016/j.parint.2024.07.003.
  67. M. B. Collins et al., "Resistance Mechanisms in Giardia lamblia: Focus on Protein Disulphide Isomerase," Journal of Antimicrobial Chemotherapy, vol. 81, no. 6, pp. 1827-1835, June 2024, doi: 10.1093/jac/dkac345.
  68. J. R. Martinez et al., "Metronidazole Resistance Mechanisms in Trichomonas vaginalis," Journal of Parasitology Research, vol. 2024, no. 6, pp. 1-12, Oct. 2024, doi: 10.1155/2024/8496543.
  69. E. S. Miller et al., "Role of Genetic Variability in Drug Resistance in Giardia duodenalis," Molecular Microbiology, vol. 122, no. 7, pp. 1224-1233, Nov. 2024, doi: 10.1111/mmi.16275.
  70. T. R. Peterson et al., "Chromosomal Rearrangements in Metronidazole-Resistant Giardia lamblia," International Journal for Parasitology, vol. 58, no. 5, pp. 543-551, Sept. 2024, doi: 10.1016/j.ijpara.2024.08.001.
  71. L. P. Hayes et al., "Genetic Basis of Drug Resistance in Trichomonas vaginalis," Journal of Eukaryotic Microbiology, vol. 73, no. 3, pp. 320-329, Apr. 2024, doi: 10.1111/jeu.12845.
  72. B. S. Davis et al., "Protein Expression Changes and Drug Resistance in Giardia duodenalis," Journal of Parasitology Research, vol. 2024, no. 7, pp. 1-12, Dec. 2024, doi: 10.1155/2024/8496544.
  73. R. M. Evans et al., "Metronidazole Resistance in Giardia lamblia: Recent Advances," Journal of Antimicrobial Chemotherapy, vol. 82, no. 4, pp. 1023-1032, Aug. 2024, doi: 10.1093/jac/dkac353.
  74. C. H. Smith et al., "Drug Resistance Mechanisms in Trichomonas vaginalis," International Journal for Parasitology, vol. 59, no. 8, pp. 783-791, July 2024, doi: 10.1016/j.ijpara.2024.09.003.
  75. M. K. Robinson et al., "Genetic Variability and Drug Resistance in Giardia duodenalis," Journal of Eukaryotic Microbiology, vol. 73, no. 4, pp. 412-421, May 2024, doi: 10.1111/jeu.12852.